Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + ipilimumab + nivolumab
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cabozantinib + ipilimumab + nivolumab is a triplet combination therapy that combines a tyrosine kinase inhibitor (cabozantinib) with two immune checkpoint inhibitors (ipilimumab and nivolumab). This combination has been studied primarily for advanced renal cell carcinoma (RCC) and other genitourinary tumors. The triplet therapy works through complementary mechanisms: cabozantinib inhibits multiple receptor tyrosine kinases involved in tumor growth and angiogenesis (including MET, VEGFR, and the TAM family of kinases), while nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) promote antitumor immune responses through different but complementary immune checkpoint inhibition pathways.
- Other names
- CaboNivoIpicabozantinib + nivolumab + ipilimumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on cabozantinib + ipilimumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + ipilimumab + nivolumab.